Top 5 pediatric health headlines you missed in June 2026

In this monthly recap, Contemporary Pediatrics reviews the most significant developments shaping pediatric practice and public health. Click each title below for full coverage.

1. FDA clears new sunscreen ingredient for children 6 months and older

On June 9, 2026, the FDA approved bemotrizinol as a new active sunscreen ingredient under the OTC monograph—the first such clearance in nearly two decades—for use in adults and children as young as 6 months, adding a broad-spectrum UV filter option to the pediatric sun-protection toolkit.

2. AAP updates guidance on pediatric iron deficiency screening and treatment

The American Academy of Pediatrics released updated clinical guidance on the prevention, screening, diagnosis, and treatment of iron deficiency and iron deficiency anemia, expanding its recommendations to include children and adolescents through age 18 years. The report recommends universal screening with a complete blood count and serum ferritin for breastfed infants between 9 and 12 months of age, formula-fed infants between 15 and 18 months, and female adolescents within 1 year after menarche or by age 14 years. Updated ferritin thresholds are intended to improve early detection before anemia develops, and the guidance endorses once-daily ferrous sulfate as first-line treatment for most children and adolescents with iron deficiency anemia. The report also outlines indications for referral and intravenous iron therapy in patients with severe, recurrent, or treatment-resistant disease. By emphasizing earlier identification and simplified treatment strategies, the recommendations aim to reduce the long-term neurodevelopmental and cognitive consequences associated with iron deficiency during childhood and adolescence.

3. FDA issues Warning Letter to SNOO Smart Sleeper maker over unauthorized sleep sacks, hospital bundle, and quality system failures

A multistate infant botulism outbreak linked to Nara Organics Whole Milk Organic Powdered Infant Formula prompted a nationwide voluntary recall after 3 infants in California, Pennsylvania, and Washington were hospitalized with confirmed botulinum toxin type A infections. All infants were treated with BabyBIG, the only FDA-approved therapy for infant botulism, and no deaths were reported. Although no recalled formula lots have tested positive for Clostridium botulinum, epidemiologic evidence led the FDA to recommend recalling all lots currently on the market. The outbreak highlights ongoing concerns about the safety of powdered infant formula, which is not required to undergo routine testing for spore-forming organisms such as C. botulinum. For pediatricians, the cases reinforce the importance of recognizing infant botulism early in infants presenting with constipation, hypotonia, poor feeding, or progressive weakness and initiating treatment promptly based on clinical suspicion without waiting for laboratory confirmation.

4. FDA and CDC investigating multistate infant botulism outbreak linked to recalled Nara Organics powdered infant formula

A multistate infant botulism outbreak linked to Nara Organics Whole Milk Organic Powdered Infant Formula prompted a nationwide voluntary recall after 3 infants in California, Pennsylvania, and Washington were hospitalized with confirmed botulinum toxin type A infections. All infants were treated with BabyBIG, the only FDA-approved therapy for infant botulism, and no deaths were reported. Although no recalled formula lots have tested positive for Clostridium botulinum, epidemiologic evidence led the FDA to recommend recalling all lots currently on the market. The outbreak highlights ongoing concerns about the safety of powdered infant formula, which is not required to undergo routine testing for spore-forming organisms such as C. botulinum. For pediatricians, the cases reinforce the importance of recognizing infant botulism early in infants presenting with constipation, hypotonia, poor feeding, or progressive weakness and initiating treatment promptly based on clinical suspicion without waiting for laboratory confirmation.

5. FDA grants accelerated approval to teplizumab for newly diagnosed stage 3 type 1 diabetes

On June 12, 2026, the FDA granted accelerated approval to teplizumab (Tzield) for a second pediatric indication: delaying further decline of insulin production in patients aged 8 to 17 years recently diagnosed with stage 3 T1D. This marks the first FDA-approved treatment for this indication and a second major pediatric milestone for teplizumab within the same quarter.